3 Edwards Lifesciences Corp. Analyst Ratings, Earnings, Dividends and Insider Trades | $EW | NYSE:EW | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Edwards Lifesciences Corp. Company Profile (NYSE:EW) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Edwards Lifesciences Corp. (NYSE:EW) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 3 Sell Rating(s), 9 Hold Rating(s), 7 Buy Rating(s)Consensus Rating:Hold (Score: 2.21)Consensus Price Target: $74.56 (3.45% upside) Analysts' Ratings History for Edwards Lifesciences Corp. (NYSE:EW) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare3/7/2014CRT CapitalBoost Price TargetFair Value$72.00 -> $79.00View 3/6/2014Northland SecuritiesBoost Price Target$90.00View 2/20/2014BTIG ResearchInitiated CoverageNeutralView 1/28/2014Leerink SwannBoost Price Target$72.00 -> $80.00View 1/27/2014ZacksDowngradeNeutral -> Underperform$63.00View 1/14/2014Canaccord GenuityBoost Price Target$74.00 -> $78.00View 12/10/2013BarclaysLower Price TargetEqual Weight$68.00 -> $64.00View 12/10/2013Citigroup Inc.Reiterated RatingBuy$75.00 -> $72.00View 12/10/2013Canaccord GenuityReiterated RatingBuy$76.00 -> $74.00View 12/10/2013Wells Fargo & Co.DowngradeOutperform -> Market PerformView 11/26/2013CRT CapitalInitiated CoverageFair Value$72.00View 11/4/2013Deutsche BankLower Price TargetHold$73.00 -> $61.00View 10/30/2013RBC CapitalLower Price TargetSector Perform$75.00 -> $60.00View 10/30/2013Northland Capital PartnersBoost Price TargetOutperform$74.00 -> $80.00View 10/30/2013BarclaysLower Price TargetEqual Weight$72.00 -> $68.00View 10/30/2013Jefferies GroupLower Price TargetBuy$85.00 -> $80.00View 10/30/2013Canaccord GenuityLower Price TargetBuy$94.00 -> $76.00View 10/30/2013ZacksReiterated RatingNeutral -> Neutral$73.00View 10/30/2013JPMorgan Chase & Co.DowngradeNeutral -> Underweight$64.00 -> $62.00View 10/29/2013BMO Capital MarketsBoost Price TargetMarket Perform$69.00 -> $73.00View 10/29/2013RBC CapitalReiterated RatingHold$75.00View 10/29/2013Canaccord GenuityBoost Price TargetBuy$90.00 -> $94.00View 10/16/2013Citigroup Inc.UpgradeNeutral -> Buy$75.00 -> $86.00View 10/3/2013RBC CapitalReiterated RatingHold$75.00View 10/3/2013Stifel NicolausBoost Price TargetBuy$81.00 -> $82.00View 9/10/2013Canaccord GenuityReiterated RatingBuy$90.00View 9/10/2013RBC CapitalBoost Price TargetSector Perform$72.00 -> $75.00View 8/29/2013ZacksUpgradeUnderperform -> Neutral$74.00View 8/22/2013Canaccord GenuityBoost Price TargetBuy$85.00 -> $90.00View 7/18/2013Northland Capital PartnersUpgradeMarket Perform -> Outperform$74.00View 7/8/2013Credit SuisseUpgradeNeutral -> OutperformView 6/13/2013Deutsche BankLower Price TargetBuy$75.00View 6/10/2013Canaccord GenuityReiterated RatingBuy$85.00View 6/10/2013Credit SuisseUpgradeNeutral -> Outperform$73.00 -> $77.00View 6/7/2013ZacksDowngradeNeutral -> Underperform$60.00View 6/3/2013Goldman SachsReiterated RatingBuyView 5/14/2013Jefferies GroupReiterated RatingBuyView 5/8/2013BarclaysLower Price TargetEqual Weight$75.00 -> $72.00View 5/7/2013JPMorgan Chase & Co.Lower Price TargetNeutral$68.00 -> $64.00View 4/30/2013Credit SuisseLower Price TargetNeutral$88.00 -> $73.00View 4/25/2013S&P Equity ResearchBoost Price TargetBuy$57.00 -> $80.00View 4/25/2013Northland SecuritiesUpgradeUnderperform -> Market PerformView 4/25/2013Northland Capital PartnersUpgradeUnder Perform -> Market Perform$75.00 -> $68.00View 4/24/2013JPMorgan Chase & Co.Lower Price TargetNeutral$82.00 -> $68.00View 4/24/2013Deutsche BankLower Price TargetHold$90.00 -> $80.00View 4/24/2013BMO Capital MarketsLower Price TargetMarket Perform$90.00 -> $78.00View 4/24/2013ZacksReiterated RatingNeutral -> Neutral$87.00View 4/24/2013Canaccord GenuityLower Price TargetBuy$115.00 -> $85.00View 4/24/2013WunderlichLower Price TargetHold$98.00 -> $74.00View 4/24/2013UBS AGLower Price TargetSell$82.00 -> $64.00View 4/24/2013Stifel NicolausLower Price TargetBuy -> Average$113.00 -> $81.00View 4/24/2013Leerink SwannLower Price TargetOutperform$100.00 -> $85.00View 4/24/2013Jefferies GroupSet Price TargetBuy$114.00 -> $85.00View 4/24/2013RBC CapitalDowngradeOutperform -> Sector Perform$102.00 -> $72.00View 4/24/2013Lazard Ltd.DowngradeBuy -> Neutral$100.00View 3/28/2013Goldman SachsLower Price TargetBuy$112.00 -> $106.00View 3/22/2013JPMorgan Chase & Co.Reiterated RatingNeutral$88.00 -> $82.00View 3/19/2013Credit SuisseLower Price TargetNeutral$96.00 -> $88.00View 3/4/2013ZacksReiterated RatingNeutral -> Neutral$90.00View 2/6/2013ZacksReiterated RatingNeutral -> Neutral$91.00View 2/5/2013BarclaysBoost Price TargetEqual Weight$85.00 -> $95.00View 2/5/2013Jefferies GroupRaise EstimatesBuy$114.00 -> $114.00View 2/4/2013Citigroup Inc.Reiterated RatingNeutral$100.00View 2/4/2013Canaccord GenuityReiterated RatingBuy$115.00View 1/31/2013Janney Montgomery ScottInitiated CoverageBuyView 1/10/2013ZacksUpgradeUnderperform -> Neutral$98.00View 1/9/2013William BlairReiterated RatingOutperformView 1/4/2013Deutsche BankBoost Price TargetHold$85.00 -> $90.00View 1/4/2013JMP SecuritiesInitiated CoverageMarket PerformView 12/5/2012Citigroup Inc.Raise EstimatesNeutral$98.00View 12/3/2012JPMorgan Chase & Co.Lower Price TargetNeutral$87.00 -> $86.00View 11/19/2012Stifel NicolausInitiated CoverageBuy$113.00View 11/14/2012UBS AGDowngradeNeutral -> Sell$95.00 -> $80.00View 11/13/2012Wells Fargo & Co.Reiterated RatingOutperformView 10/30/2012ZacksDowngradeNeutral -> Underperform$79.00View 10/22/2012JPMorgan Chase & Co.Reiterated RatingNeutral$87.00View 10/22/2012Credit SuisseCut EstimatesNeutral$96.00View 10/22/2012Goldman SachsBoost Price TargetBuy$107.00 -> $109.00View 10/22/2012Citigroup Inc.DowngradeBuy -> Neutral$95.00View 10/22/2012WunderlichLower Price TargetHold$104.00 -> $98.00View 10/9/2012Canaccord GenuityReiterated RatingBuy -> Buy$109.00View 10/9/2012Goldman SachsReiterated RatingBuy -> BuyView 10/9/2012BarclaysLower Price TargetOverweight$90.00 -> $85.00View 10/9/2012Leerink SwannReiterated RatingOutperformView 10/9/2012UBS AGLower Price TargetNeutral$110.00 -> $95.00View 10/9/2012Piper JaffrayLower Price TargetOverweight$118.00 -> $105.00View 10/9/2012RBC CapitalDowngradeTop Pick -> OutperformView 10/5/2012ZacksReiterated RatingNeutral -> Neutral$115.00View 9/28/2012Jefferies GroupBoost Price TargetBuy -> Buy$115.00 -> $125.00View 9/7/2012Northland SecuritiesUpgradeUnderperformView 9/7/2012Northland SecuritiesInitiated CoverageUnder Perform$72.00View 9/4/2012Canaccord GenuityReiterated RatingBuyView 8/6/2012Goldman SachsReiterated RatingBuy -> BuyView 8/6/2012RBC CapitalDowngradeTop Pick -> Outperform$105.00View 8/1/2012ZacksReiterated RatingNeutral -> Neutral$106.00View 7/25/2012Canaccord GenuityReiterated RatingBuyView 7/25/2012JPMorgan Chase & Co.Lower Price Target$96.00 -> $93.00View 7/25/2012WunderlichBoost Price TargetHold$75.00 -> $104.00View 7/13/2012Credit SuisseDowngradeOutperform -> Neutral$110.00View 7/6/2012Piper JaffrayBoost Price Target$118.00View 6/26/2012UBS AGDowngradeBuy -> Neutral$98.00 -> $107.00View 6/25/2012Canaccord GenuityReiterated RatingBuy$103.00 -> $123.00View 6/18/2012Goldman SachsBoost Price TargetBuy$102.00 -> $109.00View 6/15/2012ZacksReiterated RatingNeutral -> Neutral$102.00View 6/14/2012BMO Capital MarketsBoost Price TargetMarket Perform$94.00View 6/14/2012Deutsche BankBoost Price Target$80.00View 6/14/2012Citigroup Inc.Boost Price Target$105.00View 6/14/2012Jefferies GroupReiterated RatingBuyView 6/14/2012Jefferies GroupBoost Price TargetPositive -> Positive$100.00View 6/7/2012Canaccord GenuityBoost Price TargetBuy$93.00 -> $103.00View 5/31/2012Goldman SachsDowngradeBuyView 5/18/2012Canaccord GenuityReiterated RatingBuyView 5/2/2012Canaccord GenuityReiterated RatingBuy -> PositiveView 5/2/2012Goldman SachsBoost Price TargetBuy$90.00 -> $97.00View 5/2/2012Wells Fargo & Co.UpgradeMarket Perform -> OutperformView 4/30/2012GARP ResearchReiterated RatingBuyView 4/27/2012ZacksReiterated RatingNeutral -> Neutral$86.00View 3/21/2012Canaccord GenuityReiterated RatingBuyView 3/8/2012Canaccord GenuityReiterated RatingBuyView (Data available from 3/8/2012 forward) Earnings History for Edwards Lifesciences Corp. (NYSE:EW)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare2/3/2014Q413$0.82$0.91$533.82 million$536.00 millionViewN/AView 10/28/2013Q313$0.66$0.68$490.96 million$496.00 millionViewN/AView 7/25/2013Q2 2013$0.76$0.82$514.59 million$517.20 millionViewN/AView 4/23/2013Q1 2013$0.76$0.72$518.69 million$496.70 millionViewN/AView 2/4/2013Q4 2012$0.77$0.77$499.46 million$510.50 millionViewN/AView 10/19/2012$0.56$0.58ViewN/AView 7/24/2012$0.66$0.67ViewN/AView 2/2/2012$0.59$0.62ViewN/AView 10/19/2011$0.39$0.38ViewN/AView 7/21/2011$0.50$0.49ViewN/AView 4/20/2011$0.42$0.51ViewN/AView 2/2/2011$0.53$0.55ViewN/AView (Data available from 1/1/2011 forward) Dividend History for Edwards Lifesciences Corp. (NYSE:EW)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Edwards Lifesciences Corp. (NYSE:EW)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare3/6/2014Robert W.A. SellersVPSell1,650$72.88$120,252.00View 2/6/2014Michael MussallemCEOSell29,500$66.92$1,974,140.00View 1/27/2014Michael BowlinDirectorSell1,092$68.65$74,965.80View 1/9/2014Michael MussallemCEOSell29,500$67.04$1,977,680.00View 1/6/2014Huimin WangVPSell5,600$67.14$375,984.00View 12/11/2013Patrick VerguetVPSell10,000$62.34$623,400.00View 12/5/2013Huimin WangVPSell4,650$64.65$300,622.50View 12/4/2013Michael MussallemCEOSell29,500$64.90$1,914,550.00View 10/9/2013Michael MussallemCEOSell29,500$72.63$2,142,585.00View 10/4/2013Huimin WangVPSell4,850$72.19$350,121.50View 9/12/2013Michael MussallemCEOSell29,500$71.82$2,118,690.00View 9/5/2013Huimin WangVPSell4,850$71.24$345,514.00View 8/8/2013Michael MussallemCEOSell29,500$72.28$2,132,260.00View 8/5/2013Huimin WangVPSell4,850$72.30$350,655.00View 8/1/2013Patrick VerguetVPSell20,000$73.15$1,463,000.00View 7/10/2013Michael A MussallemCEOSell29,500$65.60$1,935,200.00View 7/5/2013Huimin WangVPSell4,850$65.69$318,596.50View 6/6/2013Michael A MussallemCEOSell29,500$66.25$1,954,375.00View 6/5/2013Huimin WangVPSell4,850$65.11$315,783.50View 5/13/2013Paul C RedmondVPSell5,000$67.35$336,750.00View 5/8/2013Michael A MussallemCEOSell29,200$64.24$1,875,808.00View 5/7/2013Thomas M AbateCFOSell15,000$63.75$956,250.00View 5/3/2013Schack Wesley W VonDirectorBuy1,000$64.00$64,000.00View 5/1/2013David E I PyottDirectorBuy3,000$62.95$188,850.00View 5/1/2013John H Kehl JrVPSell12,500$62.72$784,000.00View 4/26/2013Schack Wesley W VonDirectorBuy2,000$64.95$129,900.00View 4/10/2013Michael A MussallemCEOSell35,000$83.37$2,917,950.00View 3/13/2013John H Kehl JrVPSell12,500$87.75$1,096,875.00View 10/5/2012Huimin WangVPSell6,250$109.88$686,750.00View 10/4/2012Donald E Bobo JrVPSell11,530$110.14$1,269,914.20View 8/9/2012Michael A MussallemCEOSell35,000$98.69$3,454,150.00View (Data available from 1/1/2013 forward) About Edwards Lifesciences Corp. Edwards Lifesciences Corporation (Edwards Lifesciences) is focused on technologies that treat structural heart disease and critically ill patients. A pioneer in the development and commercialization of heart valve products, Edwards Lifesciences is the manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. The Company also provides hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The products and technologies provided by Edwards Lifesciences to treat advanced cardiovascular disease or critically ill patients are categorized into three main areas: Surgical Heart Valve Therapy, which combines surgical heart valves and Cardiac Surgery Systems; Transcatheter Heart Valves; and Critical Care, which includes Vascular. In October 2012, it acquired BMEYE B.V. Headlines: (3/6) US close: Stocks flat, S&P 500 pauses at record after weak data (3/3) 3 Healthcare Picks with Bullish Volume (2/20) Frontrunning: February 20 Industry, Sector and Symbol: Sector: Healthcare Industry: Health Care Equipment & Supplies Sub-Industry: Health Care Equipment Exchange: NYSE Symbol: EW CUSIP: 28176E10 Key Metrics: Previous Close: $72.3050 Day Moving Average: $67.8579200 Day Moving Average: $68.4562 P/E Ratio: 21.02P/E Growth: 1.96Market Cap: $7.729BCurrent Quarter EPS Consensus Estimate: $3.01 EPS Additional Links: View EW on Google FinanceView EW on Yahoo FinanceView EW's Company Profile on ReutersSearch for Edwards Lifesciences Corp. on Google Edwards Lifesciences Corp. (NYSE:EW) Chart for Saturday, March, 8, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.